Trial Profile
A non-randomized prospective clinical study to examine suppression of intraocular vascular endothelial growth factor during aflibercept treatment of age-related macular degeneration
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 11 Dec 2015
Price :
$35
*
At a glance
- Drugs Aflibercept (Primary)
- Indications Age-related macular degeneration
- Focus Therapeutic Use
- 11 Dec 2015 New trial record